Newsletter · · Ashutosh Agarwal

Medicare Starts Paying for Weight Loss Drugs as UnitedHealth Roars Back - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of July 18, 2026

Healthcare-policy podcast intelligence for the week of July 11 to 18, 2026. Medicare's new GLP-1 Bridge Program started covering weight-loss drugs for a $50 copay while paying Lilly and Novo about $245 a month, UnitedHealth posted a blowout quarter, and podcasts dug into the star-ratings litigation, the regional managed-care shakeout, and the Medicaid squeeze.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of July 18, 2026: Medicare Starts Paying for Weight Loss Drugs as UnitedHealth Roars Back

Intro

This was the week the policy debate stopped being about whether the government would touch the drug and insurance business and became about what happens now that it has. On July 1, Medicare, for the first time in its history, began paying for weight-loss drugs. Within two weeks, a chorus of podcasts was arguing over whether that program will be a quiet triumph or an operational trainwreck. Meanwhile, UnitedHealth, the giant that melted down last year, reported a blowout quarter and its stock jumped again. And in the quieter corners of the healthcare-podcast world, insurance agents, Medicaid-plan executives, and pharmacy experts were describing, in plain, sometimes blunt terms, how the plumbing of American healthcare actually works, and where policymakers are about to break something by trying to fix it.

Below is what the people closest to the action are saying, who they are, and why it matters for the companies you follow.

TL;DR

  • Medicare's new GLP-1 "Bridge Program" is live, charging patients a flat $50 a month while paying Eli Lilly and Novo Nordisk about $245 a month, the first time a big buyer has openly set a price floor for these drugs. Experts are split on whether millions will actually sign up or whether the program buckles under its own operational mess.

  • UnitedHealth staged a real comeback: Q2 revenue of $112 billion, EPS of $6.38, and its medical-cost ratio dropping to 86.2% from 89.4% a year ago. Wall Street pundits called it "Medicare Advantage nirvana", and pointedly noted the hospital chains are the ones getting squeezed.

  • The managed-care map is splitting in two: national carriers are winning while regional plans retreat (one New Mexico plan is dropping ~30,000 Medicare Advantage members after $59 million in losses), and Medicaid insurers are staring down eligibility changes from last year's big federal law that they say will leave them with sicker, costlier members and less money.

What's new

1. Medicare starts paying for weight-loss drugs, the "GLP-1 Bridge Program." As of July 1, Medicare Part D beneficiaries can get GLP-1 drugs prescribed specifically for weight loss for a flat $50 copay per month. On Consumerpedia, "GLP-1 Weight Loss Drugs" (July 16), Kevin Moss of Checkbook.org, a benefits expert, so treat this as informed pundit commentary, explained why this is such a big deal: "When Medicare Part D was originally written, Congress explicitly excluded coverage for drugs associated with weight loss." Until this month, seniors could only get these drugs if they had diabetes or heart disease. Now, with a doctor's prior authorization and a qualifying body-mass index (35 or higher, or 27 with an underlying condition), they can get Wegovy or the QuickPin version of Zepbound for $50. Moss called it possibly "the biggest rollout of prescription drug coverage in the history of Medicare." One catch he flagged: because the program runs outside your normal Part D plan, the money you spend does not count toward your deductible or the $2,100 annual out-of-pocket cap. Why it matters: This is direct new demand, and new revenue, for Lilly (LLY) and Novo (NVO), and a fresh cost line for Medicare. It also reshuffles the employer market: Moss noted that 11% of employers have dropped or plan to drop GLP-1 coverage, and more than a quarter of big companies are adding hurdles like mandatory weigh-ins or meal-tracking apps.

2. CMS quietly set a price for GLP-1s, and that anchor may matter more than the headline. On 4sight Health Roundup, "Unlocking the Healthcare Market Implications of GLP-1 Drugs" (July 16), healthcare strategist Julie Murchinson (pundit) made the point most coverage missed: "CMS just did something that no commercial payer has been willing to do. They set a price anchor, like the $245 net… They negotiated a floor." She argued that if the program's data shows better adherence and downstream savings, "those numbers are going to become the reference point that every PBM and employer benchmarks against." Co-host Dave Johnson put the cost in perspective: Medicare is paying Lilly and Novo roughly $245 per month per prescription, a $195-per-person subsidy on top of the patient's $50, and reminded listeners how far prices have already fallen: "It wasn't that long ago that the monthly cost for Wegovy… was $1,350 a month. And that's now down to $245 for the government." Why it matters: A transparent government price this large becomes a gravitational pull on the entire market. It is bullish for volume and access but sets a visible ceiling that private payers will point to in their own negotiations.

3. UnitedHealth's turnaround is real, and the numbers are big. UnitedHealth (UNH) reported on July 16, and the market noticed. As laid out on The Rundown, "TSMC Profit Surges 77%…" (July 16), the largest private health insurer in America posted revenue of $112 billion and EPS of $6.38, both beating estimates. The standout was cost control: its medical-cost ratio, the share of premium dollars paid out for care, improved to 86.2%, down from 89.4% a year earlier (a lower number means the insurer keeps more of each premium dollar). On Schwab Network (July 16), the host added the guidance: UNH raised full-year EPS guidance to $19.50–$20.00, up from $18.25, on about $439 billion of expected revenue, crediting $1.5 billion invested in AI, streamlined operations, and "getting rid of some of the unprofitable contracts." Why it matters: This is the clearest sign yet that the cost spike that gutted managed-care earnings in 2025 is being brought back under control, at least at the biggest player. The stock was already up 27% for the year coming into the print and rose another ~7% on the day.

4. The Medicare Advantage "star ratings" war heats up, Elevance sues CMS. On The Seven Figures Or Bust Podcast!, "Episode 249: Elevance Sues CMS! What To Know" (July 13), the hosts, Medicare insurance agents who sell these plans, so frontline operators rather than carrier executives, walked through why star ratings are the whole ballgame. Medicare grades each plan on a 1-to-5 scale using up to 43 quality measures across five areas (preventive care, managing chronic conditions, member experience, complaints, and customer service). The catch, they argued, is that the score barely reflects how good the benefits are: "You'll have plans in a market where a plan will have a five-star rating, and you look at the benefits, and it might be a dumpster fire plan." The money at stake is enormous, "every half star could be worth tens of millions of dollars to the carriers," and for a national player like Anthem/Elevance, "we could be talking into the billions" of dollars in annual funding. The backstory: rival insurer Clover sued CMS after its rating slipped to 3.5 stars, and in late May a Georgia federal judge ordered CMS to recalculate Clover's rating without 10 disputed measures. Elevance's argument, as the hosts read it: you can't fix it for one carrier that sued you and not for everyone else. Why it matters: Star ratings are a direct earnings input for every MA insurer (UNH, HUM, CVS/Aetna, ELV, CNC, CI). A wave of litigation and a judge second-guessing CMS's methodology injects real uncertainty into a number that swings billions in bonus payments.

5. A regional insurer walks away from Medicare Advantage, and it's a trend. On The Seven Figures Or Bust Podcast!, "Episode 251: Regional Carrier Pulls Out Of Medicare Advantage: 30,000 to terminate!" (July 17), the same agent-hosts (operators) detailed how Presbyterian Health Plan in New Mexico will stop offering most of its Medicare Advantage plans in 2027, citing losses that "contributed to more than $59 million in losses for Presbyterian in 2025," with roughly 150 jobs cut. Fitch downgraded the parent to AA- from AA in February with a negative outlook. And it isn't isolated: "Providence Health Plan recently announced it was ending most of its health insurance business beginning in 2027." Their takeaway was blunt: "The big guys are going to be the ones that survive… they figured out diversification of revenue geographically. They will win the war of attrition." As counter-evidence of the strong getting stronger, they cited Humana expecting 25% MA membership growth this year and Clover growing membership 51% year-over-year to 155,773 with 95% retention. Why it matters: Consolidation into the national carriers is accelerating. Regional and provider-owned plans, more exposed to a single local market, are the ones exiting, which over time hands share to the scaled incumbents.

The debate

Will Medicare's GLP-1 Bridge Program be a runaway success or an operational mess? This is the one genuine, two-sided argument the podcasts actually supported this week, and both sides came from the same conversation on 4sight Health Roundup (July 16).

The bullish case (Dave Johnson): Demand is overwhelming and the pipeline of benefits is only growing. Johnson argued that a low uptake estimate he'd seen (around 4 million) "seems wildly low to me. There are already 30 million users… of GLP-1 drugs. 80% of elderly Americans… have elevated sugar levels and are already diabetic or pre-diabetic. That's 50 million people. So the train has already left the station." His view: prices keep falling, the science keeps improving, and "you've got to believe prices are going to come down with broader market access."

The bearish case (Julie Murchinson): The program was bolted onto a system that can't handle it. She bet enrollment "is lower than they think it's going to be," warned that pharmacies often "don't necessarily know at the point of sale whether a script goes through Bridge or Part D," that there's "no formal appeals process for denials," and that "the supply chain is already a mess." Her sharpest line: "It's almost like it's a pilot that's immediately running at scale… that's bad." She expects the program to become "a case study for why the government has a very hard time getting involved in a market that's really already hot."

The swing factor: adherence and outcomes data. Both agreed that if the Bridge Program produces credible, large-scale evidence that these drugs keep people healthier and lower downstream costs, that data, not the coverage headline, becomes the argument that reshapes the whole market.

A second, quieter debate runs underneath the managed-care numbers: are national carriers structurally advantaged, or just early in the same cost cycle that will eventually bite them too? The Seven Figures Or Bust operators made the strong case for scale and geographic diversification as a durable moat. The bearish counter didn't get a full airing this week, but it's implied in the same data: the whole reason regional plans are failing, "another double-digit year" of medical trend, as one Medicaid executive put it below, is a cost problem no carrier is immune to. UnitedHealth's own 2025 collapse is the proof.

The names in play

  • UnitedHealth (UNH): The comeback story of the week. On Squawk on the Street (July 16), Jim Cramer (pundit) framed it vividly: "If they can make more money in Medicare Advantage, they just crush it. They are in a Medicare Advantage nirvana right now," and called CEO Hemsley "a miracle man." On Morning Call (July 16), portfolio manager Stephanie Link (pundit), who owns the stock, said Hemsley "repriced all of their membership… they are laser-focused on cost cuts and discipline," and argued it's still cheap at "17 times earnings and about 18 times EBITDA" versus a historical "20s" multiple: "I think you should buy it. And I might even buy some more."

  • HCA / hospitals (HCA, THC, UHS): The flip side of UNH's win. Cramer, on Squawk on the Street, argued the two are linked: "UNH, they win. HCA gets stiffed." His read on the hospital pain was specific, it wasn't fewer procedures, it was testing (he named LabCorp and Quest) and unpaid bills from patients "who went into the hospital without insurance… and then didn't pay."

  • CVS Health (CVS): On Washington Welcomes, "David Joyner, Chairman and CEO of CVS Health" (July 14), the CEO himself (operator/insider) spoke candidly about the 2018 $69 billion Aetna acquisition: the idea was to fix a "very fragmented" system, but "we haven't evolved and matured that across the country to the degree that I'm hoping we'll get there." On growth, he pointed past the store count to the sheer size of the spending pool: "We're expected to pay $6 trillion for health care in 2026… by the time we get to 2034, it'll be $9 trillion." Cramer, separately, was bullish: "Joyner's winning two ways. He's winning in the front of the store because Walgreens is out, Rite Aid is out… and he's winning in the back because Aetna's doing very well."

  • Humana (HUM): Mostly a chart story this week. On Stock Market Today With IBD, "Hormuz Troubles Help Oil Lead; …Humana In Focus" (July 13), the hosts noted Humana sits in a managed-care industry group that "ranks very nicely, 9 out of 145," with a breakout that "has held," though the stock "looks a little bit extended." No fundamental news, a technical read only.

  • Eli Lilly (LLY) and Novo Nordisk (NVO): The direct beneficiaries of Medicare's new coverage (see "What's new"). On 4sight Health Roundup, Johnson noted GLP-1s "have made Lilly the first trillion-dollar medical company in history."

  • Elevance (ELV) / Anthem and Clover Health: At the center of the star-ratings litigation battle (see "What's new," item 4).

Read-throughs

  • PBMs (and generics/biosimilars): The most substantive drug-pricing discussion of the week was a warning aimed straight at policymakers. On Relentless Health Value, "Cash-Pay Generic Drugs Are a Functioning Market in Healthcare, Policymakers Beware and Be Careful. EP520" (July 15), host Stacey Richter and a panel of pharmacy experts (industry pundits) argued that cheap generics are the one genuinely competitive market in US healthcare, and that pushing them through insurance and PBMs makes them more expensive, not less. The numbers are striking: among the 20 most-prescribed generics, "43% of them actually will have a higher out-of-pocket payment from patients than the GoodRx price," rising to "79% of the prescriptions" for people still in their deductible. The panel estimated the PBM "is extracting $41 out of every $100 spent on generic drugs that cost on average like 47 cents to manufacture." They also flagged a specific contract mechanism, "most favored nation" or "lesser-of" clauses between PBMs and pharmacies, that punish a pharmacy for lowering its cash price, and separately noted that generic uptake has slowed from reaching "57% of their peak… within one month of launch" (2009–2013) to "six months on average" now. The read-through: any policy that tries to make generics cheaper by routing them through the insurance layer risks the opposite result, a live risk as Washington keeps hunting for drug-price wins.

  • Medicaid and exchange insurers (CNC, MOH, ELV): This is where the pain is concentrating. On Soaring to New Health, "The State of Managed Care: What Health Plans Must Get Right in 2026" (July 16), two executives of Highmark Wholecare, a Pennsylvania Medicaid plan (operators/insiders), described the squeeze in detail. Industry margins "fell to under 1%, or less than a negative 0.9%" in 2024. Enrollment has dropped for "the last 12 to 18 months," and with the state exchange's "subsidies few and far between," disenrolled members "end up in an emergency room" uninsured, raising costs for everyone. Last year's federal law (referred to as "HR1" / "OB-3," i.e., the reconciliation bill) forces new eligibility checks, "over 750,000 Pennsylvanians" will have to renew twice a year, and the executives warned of a classic adverse-selection problem: "it's usually the healthy 200 that leave, not the sickest 200," so the members who stay are sicker and costlier. They also flagged "over $2 billion of lost revenue" the state must now make up, and a medical-cost trend running at "another double-digit year" in 2026.

  • Optum-style services / vertical integration: CVS CEO David Joyner's comments on Washington Welcomes are the clearest recent operator view on whether combining insurance, pharmacy, and care delivery actually works. His honest verdict, that the integrated model "hasn't fully matured nationally" eight years after the Aetna deal, is a caution for the whole "own the whole stack" thesis (Optum at UNH, Aetna/CVS Caremark at CVS).

  • Hospitals (HCA, THC, UHS): Beyond Cramer's "HCA gets stiffed" comment, Thoughts on the Market, "Why Your Medical Bill Is So High" (July 17) offered a Morgan Stanley framework: hospitals have been "absorbing… rising costs of healthcare through lower margins," billing/insurance negotiation alone can eat "2% to 4% of revenue" (up to 5–7% in complex cases), and because Medicare "does not fully reimburse for the cost of care," commercial prices for the privately insured "are likely to rise even faster" as the population ages. Their conclusion: hospital price increases are coming, but slowly, "the biggest benchmark setting of prices happens once every two to three years."

  • GLP-1 cost exposure for insurers: The Highmark executives on Soaring to New Health offered a useful nuance: their state addressed GLP-1 costs for 2026 and is "seeing the benefits," which helped "bend that cost curve", yet overall pharmacy spend is still up "6-plus percent," because "specialty drugs" now run "over 50 percent of pharmacy costs," up from "roughly 20 percent" a decade ago. GLP-1s are a headline cost, but they're one piece of a broader specialty-drug surge.

  • Ex-US: No meaningful most-favored-nation, pharma-tariff, or ex-US pricing discussion surfaced in this week's podcasts. The closest was Joyner noting the US system is "an N of one", a uniquely private-sector model that "doesn't export well" to countries with national payers.

What changed

  • Medicare now covers weight-loss drugs. The single biggest change: the GLP-1 Bridge Program went live July 1, ending Medicare's decades-old statutory exclusion of weight-loss drugs. That's a genuine new fact on the ground, not a proposal.

  • The managed-care cost narrative has flipped at the top. A year ago the story was UnitedHealth's historic cost blowup; this week it was a beat-and-raise with the medical-cost ratio down more than three points year-over-year. The turnaround is now showing up in the numbers, not just the commentary.

  • Regulatory risk on star ratings is escalating from grumbling to litigation. A federal judge ordering CMS to recalculate a plan's rating, plus Elevance suing, moves this from a perennial complaint to an active legal fight over how billions in bonus payments get set.

What did not change this week: there was no new IRA news (no 2028 selected-drug-list detail, no Part D redesign specifics), and no new most-favored-nation or pharma-tariff executive action came up in any podcast, worth noting given how much attention those topics usually draw.